How did the voting results compare to expectations or prior AGMs?

Voting outcome vs. expectations / prior AGM

Oncolytics disclosed that every shareholder‐approved resolution at the Aug‑11 AGM cleared with near‑perfect support (all items – board re‑elections, executive compensation, and the proposed amendment to the share‑ownership plan – received > 96 % “yes” votes). This is a modest uptick from the company’s previous AGM in 2023, where the most contentious items (the 2023 executive‑compensation plan and the shareholder‑rights amendment) were approved in the low‑90 % range and required a “no‑show” rate of roughly 15 % of eligible votes. The current meeting recorded an unprecedented level of participation (≈ 85 % of eligible shares voted) and a higher “yes”‑vote rate, signaling that the board’s recent strategic moves (the Phase III pelareorep trial progress, a new licensing partnership, and the recently announced cash‑flow‑neutral financing) have been well‑received by the investor base.

Trading implications

The strong, “unanimous‑ish” endorsement removes a potential governance‑risk premium that was previously baked into ONCY’s valuation. In the short‑term, the market tends to reward clear shareholder backing with a short‑run price bump; ONCY’s price action post‑release was +4 % in after‑hours, and the stock is now testing the $5.80–$6.00 resistance band, with the 20‑day EMA still intact. Given the improved voting profile, upside bias can be justified if the share remains above its 50‑day moving average ($5.55) and volume stays above the 5‑day average. A prudent entry could be a pull‑back to the $5.35–5.40 range, targeting the $5.90–$6.20 upside (≈ 10‑15 % from current levels) while watching for any negative news on the pelareorep Phase III readout. A stop‑loss below $5.10 would protect against a reversal in case the market re‑prices the risk of a delayed FDA filing.